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Clinical studies have shown that medical and device thera-
pies that reduce heart failure morbidity and mortality also
lead to a decreased left ventricular (LV) volume and mass
and restore a more normal elliptical shape to the ventricle.
These changes are due to the changes in myocyte size,
structure, and organization that, on a global level, are
reflected in shifts of the LV end-diastolic pressure–volume
relationship toward normal. For want of better terminology,
these changes, which encompasses myriad changes at the
molecular, cellular, tissue, and organ level, have been re-
ferred to as “reverse remodeling” (1,2). More recently, it has
also become clear that a subset of patients whose hearts have
See page 2170
undergone reverse remodeling after support with a mechan-
ical circulatory ventricular assist device (VAD) are able to be
weaned from their VADs, which has been referred to as
“myocardial recovery” (3). These observations have engendered
a great deal of interest, insofar as they may provide insight into
developing novel therapies that actually reverse heart failure, as
opposed to preventing it from progressing (4).
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Circulite.In this issue of the Journal, Ramani et al. (5) examined the
expression levels of noncoding ribonucleic acids (RNAs),
termed microRNAs (miRs [see Topkara and Mann (6) for
a review of microRNA biology]) in 28 patients with
nonischemic heart failure who underwent VAD placement,
to determine whether there was a relationship between the
expression levels of microRNAs at the time of VAD
implantation and the ability of the heart to recover after
VAD support. This study included a test cohort of 14
patients and a validation cohort of 14 patients from a
separate institution. Fourteen of the patients underwent
removal of their VAD (LV recovery group, n  7 from the
test cohort and 7 from the validation cohort), whereas the
other 14 patients remained VAD dependent. Apical myo-
cardial cores, obtained at the time of implantation, were
examined with respect to expression levels of 376 miRs by
polymerase chain reaction (PCR)-based array and real-time
(RT)-PCR methods at the time of VAD implantation.
MicroRNA levels were also obtained from 7 nonfailing
hearts. Moreover, microRNA levels were also examined in
the hearts of patients at the time of VAD implantation, as
well as at the time of VAD removal. Ramani et al. (5) noted
that the levels of 4 miRs, namely, miR 15b, miR 23a, miR 26a,
and miR 195, were significantly decreased in the LV
recovery hearts when compared to VAD-dependent pa-
tients in the test cohort. Importantly, the validation cohort
revealed similar findings with respect to microRNA expres-
sion levels in the LV recovery group. Of interest, there was
no difference in the expression of miR 15b, miR 23a, miR 26a,
and miR 195 levels before and after VAD implantation.
Moreover, the expression levels of miR 23a and 195 in the
LV recovery group were similar to those of nonfailing
hearts. The hearts from the LV recovery group had signif-
icantly smaller cardiomyocytes at the time of VAD implant
by quantitative histology. Ramani et al. (5) concluded that
the lower cardiac expression of miRs 23a and 195 at the
time of VAD placement was associated with subsequent LV
functional recovery and that the differential expression of
microRNAs at the time VAD placement may serve as a
potential biomarker to assess the potential of myocardial
recovery after VAD implantation.
Before discussing the clinical implications of this carefully
done study, it is helpful to digress for a moment to discuss
what is known and what is not known about myocardial
recovery in the failing heart.
Myocardial recovery and the failing heart. Despite the
frequent use of the term “myocardial recovery” to describe
the reversal of various aspects of the heart failure phenotype
after medical and device therapy, myocardial recovery has
never been defined in the medical literature. The concept
that the failing heart could “recover” became enmeshed in
the lexicon of heart failure terminology in the mid 1990s
after the observation was made that mechanical circulatory
support with VADs was consistently associated with de-
creased LV size and marked leftward shifts toward normal
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Myocardial Recovery and MicroRNAs November 22, 2011:2279–81of the LV end-diastolic pressure–volume relationship, indi-
cating that the heart was not simply unloaded but, rather,
that there were fundamental changes in the biological
properties of the heart that allowed the ventricle to return
toward normal size, shape, and function (2). Moreover,
there were anecdotal reports that some patients could be
weaned from their VAD (7,8). These early observations
were later complemented by studies of heart failure patients
treated with angiotensin-converting enzyme inhibitors and
beta-blockers, in whom significant decreases in LV end-
diastolic volume where noted compared to placebo controls
(9–11), although not to the same degree as observed with
left ventricular assist devices. Viewed together, these studies
challenged the prevailing dogma that heart failure was
irreversible and, in turn, fostered a greater interest in
understanding the biological processes responsible for res-
toration of normal cardiac structure and function. However,
our understanding of myocardial recovery has been chal-
lenged by perplexing studies in patients showing that while
mechanical unloading of the heart leads to restoration of LV
size, shape, and pressure-volume relationships, and partial
reversal of many aspects of the molecular and cellular heart
failure phenotype (12), the vast majority of patients cannot
be weaned from mechanical circulatory support (13,14).
hus, although myocardial recovery is always accompanied
y reverse remodeling, reverse remodeling does not always
esult in myocardial recovery, despite the apparent similar-
ties of these 2 processes at the anatomic, cellular, and
olecular levels (15,16). So, what exactly is myocardial
ecovery?
In the absence of a previously established working defi-
ition, we propose that myocardial recovery of a failed heart
e defined as the normalization of the molecular, cellular,
yocardial, and LV geometric changes that provoked car-
iac remodeling, that allow the heart to maintain preserved
V structure and function in the face of normal and/or
erturbed hemodynamic loading conditions. Thus, al-
Figure 1 Myocardial Recovery of the Failing Heart
Myocardial recovery of a failed heart can be defined as the normalization of the m
that provoked cardiac remodeling. Solid circles  heart failure phenotype; open c
geometry; M  myocardium (cardiocytes and extracellular matrix).though reversal of the heart failure phenotype at the cellular
(myocyte) and molecular levels is necessary for the initiation
of myocardial recovery, and is responsible for the restoration
of normal LV size and shape (i.e., reverse remodeling), the
sustainability of myocardial recovery will likely depend on
the ability of the heart to maintain preserved structure and
function in response to normal and/or perturbed hemody-
namic loading conditions (Fig. 1). Although there has been
significant work in understanding many aspects of reverse
remodeling at a phenomenological level, there has been
essentially no prior work on understanding the factors that
allow the reverse remodeled heart to maintain preserved LV
structure and function in the face of normal and/or per-
turbed hemodynamic loading conditions. Unfortunately,
the extant literature does not suggest which of the myriad
changes that occur during reversal of the heart failure
phenotype is most important and/or necessary to preserve
LV structure and function. Intuitively, one can speculate
that changes within the myocardium, including both pro-
gressive loss of cardiac myocytes, as well as the organization
of the extracellular matrix are likely to be extremely impor-
tant (17). Although current efforts have largely focused on
the changes in the type and/or volume fraction of collagen
in the reverse remodeled heart, it is likely that changes in the
3-dimensional organization of collagen matrix, as well as
interactions between the collagen matrix and the resident
cardiac myocytes, will be critically important in terms of
preserving LV structure and function.
In light of the foregoing discussion, what insights can be
gleaned from the study of Ramani et al. (5) with respect to
our understanding of myocardial recovery? The observation
that the expression levels of the 4 of the microRNAs that
predicted recovery in VAD patients did not change in the
subset of patients who had microRNA levels determined
before and hemodynamic unloading, and that 2 of the
microRNAs identified (miRs 23a and 195) were similar to
the levels found in nonfailing myocardium suggests that
r, cellular, myocardial, and left ventricular (LV) geometric changes
 normal phenotype; C  cardiac myocyte biology; LV  left ventricularolecula
ircles
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severity and nature of the underlying heart failure at the
time of VAD implantation, rather than to the effect of
mechanical unloading and/or concomitant medical therapy
per se.
Although Ramani et al. (5) matched the clinical heart
failure characteristics of the recovery and the VAD depen-
dent groups meticulously, and were careful to exclude heart
failure etiologies that are known to recover (e.g., myocardi-
tis), it is possible that the stability of the miR 23a and miR 195
levels in the recovery group is a biomarker that identifies
patients with less advanced heart failure, who are more or
most likely to recover with device and/or medical therapies
when compared to patients with more advanced disease.
Indeed, the microRNAs that were identified in this study
did not have in silico-based mRNA targets that are thought
to be involved in either reverse remodeling or myocardial
recovery, suggesting that the microRNAs were not involved
mechanistically in recovery.
Thus, the provocative question raised by this study is
whether at some point the failing heart “crosses the Rubi-
con,” and that when damage to the heart eventually becomes
advanced, even though reverse remodeling may be possible,
the heart cannot maintain preserved LV structure and
function in the face of normal and/or perturbed hemody-
namic loading. Our lack of understanding regarding the key
biological differences between reverse remodeling and myo-
cardial recovery may be 1 of the root causes for our inability
to design, develop, and implement new medical therapies
for heart failure over the past decade. Given that the
economic burden imposed by the epidemic of heart failure is
rapidly approaching the tipping point, there has likely never
been a better time for funding agencies, industry, and
academia to work together to address the broader questions
raised in the important study by Ramani et al. (5).
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